Overview
- Missouri Attorney General Catherine Hanaway filed a new federal challenge seeking to halt the FDA’s Sept. 30 approval of Evita Solutions’ generic mifepristone, with Kansas and Idaho joining the suit.
- The filing asks the Eastern District of Missouri to reinstate pre‑2016 requirements, including in‑person visits, a shorter seven‑week gestational window, and an end to mail, pharmacy and telehealth dispensing.
- The case, originally brought by different plaintiffs in Texas, was transferred to St. Louis and is now assigned to U.S. District Judge Cristian Stevens, with no hearing date set.
- FDA officials maintain the drug is safe when used as directed and report 32 deaths among 5.9 million uses from 2000 to 2022, while HHS leadership said the generic approval followed legal standards for identical products.
- Mifepristone, taken with misoprostol, is used in more than 60% of U.S. abortions, and the states contend mail‑order access undermines their laws and strains health systems.